ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

purinostat

Its studies are mostly in Lymphoma, Large B-Cell, Diffuse, led by Chengdu Zenitar Biomedical Technology.

Drug pagePurinostat: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 30, 20251 company-led study, 1 open or runningNext primary completion: Jun 30, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chengdu Zenitar Biomedical Technology11 open or runningphase 3since May 30, 2025May 30, 2025Jun 30, 2029phase 3 · NCT07011056

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 30, 2025First study: phase 3 study in RecurrenceFirst studyNCT07011056 · 390 planned · China

Ahead

  1. Jun 30, 2029Primary completion: phase 3 study in RecurrenceNCT07011056

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07011056Recurrence · China3RecruitingJun 30, 2029390

How it is read

Names in the registry

  • “Purinostat Mesylate for Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.